Archives
-
Isoprenaline Hydrochloride: Evidence Guide
2026-10-05
Isoprenaline Hydrochloride, also called isoproterenol, is a non-selective β-adrenergic agonist used to study cardiac, vascular, respiratory, and heart–brain responses. A 2026 mouse study linked chronic isoproterenol exposure to tachycardia, insular-cortex activation, and PTSD-like behaviors, but the findings remain preclinical and do not establish clinical efficacy.
-
EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag)
2026-10-05
EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag) is a research-use mouse OX40L mRNA construct with an HA detection tag. R1078 supports conceptual studies of transient OX40L expression and T-cell co-stimulation, but the cited melanoma study did not test this reagent or OX40L mRNA.
-
Linagliptin and Tau Ser356: Evidence Boundaries
2026-10-04
Linagliptin (BI-1356) and tau phosphorylation occupy distinct pharmacological contexts. This article examines what Taylor et al. reported about p-tau Ser356 and NUAK inhibition, while defining the evidence needed before connecting DPP-4 biology with Alzheimer’s disease mechanisms.
-
GRE, CREB/MITF, and Multimodal Melanogenesis
2026-10-03
This 2025 cell-based study evaluates glabridin, resveratrol, ellagic acid, and their combinations across melanogenesis, antioxidant, and inflammatory readouts. Its main contribution is linking the strongest combination, GRE, with reduced CREB phosphorylation and MITF-associated signaling, while its in-vitro design limits claims about clinical efficacy, formal synergy, or treatment of hyperpigmentation disorders.
-
Post-Encapsulation Methods for mRNA-LNPs
2026-10-02
A 2025 study separates vesicle formation from mRNA loading to reduce material waste during small-volume lipid nanoparticle production. Its microfluidic and manual post-encapsulation routes produced particles and expression levels comparable to conventional microfluidic formulations, supporting more flexible formulation screening.
-
ISRIB (trans-isomer): ATF4 and Fibrosis
2026-10-01
A translational strategy for using ISRIB (trans-isomer) to interrogate PERK–eIF2α–eIF2B–ATF4 signaling in liver fibrosis, ER stress research, apoptosis, and selected CNS models—while distinguishing established evidence from testable hypotheses.
-
Fluo-4 AM for AT1R–Ca2+ Signaling
2026-10-01
Fluo-4 AM provides a bright, cell-permeant route to real-time calcium imaging. This article uses the GPR107–AT1R pathway in diabetic nephropathy to show how calcium measurements can distinguish pathway activation from downstream disease phenotypes.
-
Sulfo-Cy3 NHS Ester for Protein Labeling
2026-09-30
Sulfo-Cy3 NHS Ester is a water-compatible labeling reagent for tracking proteins, peptides, endothelial uptake, and engineered quantum-dot probes. Its sulfonated structure helps maintain solubility while its NHS ester supports efficient fluorescent labeling of amino groups under aqueous conditions.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) Workflows
2026-09-30
Separate mRNA uptake from functional protein expression with a dual-fluorescence reporter built for delivery optimization. This practical guide shows how to use Cy5 tracking, EGFP translation, and orthogonal nanoparticle characterization to improve assay interpretation and reproducibility.
-
Dinaciclib (SCH727965): CDK Mechanism and Uses
2026-09-29
Dinaciclib, also known as SCH727965, is a multi-CDK inhibitor used to study cell-cycle control, Rb phosphorylation, and apoptosis in cancer models. Its strongest evidence supports in vitro pathway interrogation and mouse xenograft research, while direct effects on developmental tissue boundaries remain un established.
-
Intravesical p21 mRNA–LNP Therapy in Bladder Cancer
2026-09-29
The reference study develops a localized, nonviral tumor-suppressor replacement strategy by delivering chemically modified CDKN1A/p21 mRNA in lipid nanoparticles directly into the bladder. Its combined molecular, cellular, biodistribution, and orthotopic-model data indicate that intravesical p21 expression can suppress tumor growth while limiting systemic exposure, although further work is needed to establish clinical durability and formulation comparability.
-
RIPA Lysis Buffer Strong for Stroke Protein Studies
2026-09-28
RIPA Lysis Buffer Strong enables rigorous protein extraction for ischemic-stroke research, where apoptosis, necroptosis, and microglial activation must be measured together. This guide connects detergent chemistry and inhibitor selection with assay-specific decisions for Western blotting, immunoprecipitation, ELISA, and kinase workflows.
-
RIPA Lysis Buffer (Strong) in Neuroimmune Research
2026-09-28
See how RIPA Lysis Buffer (Strong) can support protein analysis of macrophage–exosome–neuron signaling without confusing cell lysis with extracellular-vesicle isolation. This mechanistic guide translates findings on exosomal MMP8 and TGF-β signaling into practical choices for sample preparation and assay design.
-
Z-DEVD-FMK in Cell-Death Assay Interpretation
2026-09-27
Z-DEVD-FMK is a caspase-3 inhibitor that can help test caspase involvement—but inhibitor response alone cannot identify a cell-death pathway. This article uses ricin-triggered bystander injury to show how to interpret inhibitor results alongside orthogonal readouts and pathway-specific controls.
-
U-73122 for PLC Signaling and Invasion Assays
2026-09-26
Use U-73122 to test whether phospholipase C signaling contributes to breast cancer cell invasion, calcium responses, or chemotaxis—not simply to suppress cell movement. This workflow pairs pharmacological perturbation with pathway readouts and orthogonal controls to make results easier to interpret.